Journal of Controlled Release Submission Guide

Source: Clarivate JCR 2024, Elsevier editorial disclosures (accessed April 2026).

Source: Journal of Controlled Release author guidelines.

Use this page when deciding:

• whether the delivery-mechanism contribution is substantive
• whether in-vivo validation is included
• whether translational relevance is direct

• a clear drug-delivery mechanism contribution
• in-vivo validation appropriate to the application
• direct translational relevance
• rigorous methodology with characterization and pharmacokinetics
• a cover letter establishing the delivery contribution

• Incremental formulation reports without delivery mechanism.
• Missing in-vivo validation.
• Weak translational framing.
• Drug discovery without delivery focus.

Journal of Controlled Release is a flagship drug-delivery research journal.

Mechanism + translational standard: the journal differentiates from International Journal of Pharmaceutics (broader) and Drug Delivery (broader applied) by demanding both delivery mechanism and translational relevance.

In-vivo expectation: editors expect animal or in-vivo data on systems framed for therapeutic use.

The 40-50% desk rejection rate: decisive editorial screen.

The strongest Journal of Controlled Release cover letters establish:

• the delivery-mechanism contribution
• the in-vivo validation
• the translational relevance
• the central finding

• Is Journal of Controlled Release a good journal?
• Advanced Drug Delivery Reviews submission guide

Before upload, run your manuscript through a Journal of Controlled Release mechanism and translational readiness check.

In our pre-submission review work with drug-delivery manuscripts targeting Journal of Controlled Release, three patterns generate the most consistent desk rejections.

In our experience, roughly 35% of Journal of Controlled Release desk rejections trace to incremental formulation framing. In our experience, roughly 25% involve missing in-vivo validation. In our experience, roughly 20% arise from weak translational framing.

• Incremental formulation reports without delivery mechanism. Journal of Controlled Release editors look for delivery mechanism, not just formulation optimization. We observe submissions reporting formulation modifications without mechanism analysis routinely desk-rejected.

• Missing in-vivo validation on systems with therapeutic claims. Editors expect animal or in-vivo data on delivery systems framed for therapeutic use. We see manuscripts reporting only in-vitro data on systems with therapeutic claims routinely returned.

• Weak translational framing. Journal of Controlled Release specifically expects translational relevance. We find papers framed as nanomaterials or polymer chemistry advances with delivery as a peripheral mention routinely redirected to specialty venues. A Journal of Controlled Release mechanism and translational readiness check can identify whether the package supports a submission.

Clarivate JCR 2024 bibliometric data places Journal of Controlled Release among top drug-delivery journals.

In pre-submission diagnostic work for top drug-delivery journals, we consistently see four signals that distinguish strong submissions from weak ones. First, the contribution must be mechanism-focused, not formulation-only. Second, in-vivo validation should accompany any therapeutic claim. Third, translational relevance should be direct. Fourth, methodology should include rigorous characterization and pharmacokinetic analysis.

The single most consistent feedback class we deliver in pre-submission diagnostics for Journal of Controlled Release is the formulation-versus-mechanism distinction. Journal of Controlled Release editors expect mechanistic understanding of drug release. Submissions framed as "we developed nanoparticle formulation X with property Y" routinely receive "what is the delivery mechanism?" feedback during desk screening. We coach authors to lead with the delivery-mechanism question and frame the formulation work in service of that question. Papers framed as "we elucidated how mechanism X drives controlled release behavior Y in delivery system Z, validated in vivo with pharmacokinetic analysis" receive better editorial traction. The same logic applies across drug-delivery journals: editors are operating with limited slot inventory, and the submissions that get traction lead with the mechanism question.

Beyond the rubric checks, three pre-submission diagnostic patterns recur most often in the manuscripts we review for Journal of Controlled Release. First, manuscripts where the abstract reports formulation properties without delivery mechanism are flagged at desk for incremental framing. We recommend the abstract's central sentences state the delivery question, the mechanism, and the translational finding. Second, manuscripts where in-vivo data is reported only in supplementary materials rather than as central evidence are flagged for translational framing gaps. We recommend integrating in-vivo data into main figures. Third, manuscripts that lack engagement with Journal of Controlled Release's recent issues are at risk of being told the contribution doesn't fit the publication conversation.

The strongest manuscripts we coach distinguish themselves on three operational behaviors. First, they confine the cover letter to one page and use it to make the case for fit, contribution, and significance, not to summarize the abstract. Second, they include a one-sentence elevator pitch in the cover letter's opening that the editor can use when discussing the manuscript internally. Third, they identify the specific recent papers in the journal that this manuscript builds on and the specific competing or contradicting work; this signals the authors are operating inside the publication conversation rather than outside it.